FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

NOV 2.8 2005

ATTY. DOCKET NO. ON/4-32752A APPLICATION NO. 10/534,572 APPLICANT John Arthur Hohneker FILING DATE

MAY 11, 2005

Group

U.S.	PA	TFI	T	DO	CI	IM	FA	ITS
u.s.			**	20	•	J 117	En	

& TRADEN	W.		U.S. PATENT DOCUMENTS				
EXAMINER DITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH			· · · · · · · · · · · · · · · · · · ·			
	Al						
-	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
EVS.	AM	*WO 01/10859	02/15/01	WIPO				
•	AN							
	AO							
	AP							
	AQ							

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, Etc.)

<i>5</i> U5	AR	Ascoli, Scalzo, Facciolo and Nardi, "Platelet-Derived Growth Factor Receptor Immunoreactivity in Mesothelioma and Nonneoplastic Mesothelial Cells in Serous Effusions", <i>Acta Cytologica</i> , Vol. 39, No. 4, pp. 613-622 (1995).
	AS	Fitzpatrick, Peroni and Bielefeldt-Ohmann, "The Role of Growth Factors and Cytokines in the Tumorigenesis and Immunobiology of Malignant Mesothelioma", <i>Am J Respir Cell Mol</i> , Vol. 12, No. 5, pp. 455-460 (1995).
1	АТ	Garlepp and Leong, "Biological and Immunological Aspects of Malignant Mesothelioma", Eur Respir J, Vol. 8, No. 4, pp. 643-650 (1995).
EXAMIN	ER	DATE CONSIDERED 3/14/06

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

*FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

DN

EXAMINER

ATTY. DOCKET NO. ON/4-32752A APPLICATION NO. 10/534,572 APPLICANT John Arthur Hohneker FILING DATE MAY 11, 2005

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Klominek, Baskin and Hauzenberger, "Platelet-Derived Growth Factor (PDGF) BB Acts as a DA Chemoattractant for Human Malignant Mesothelioma Cells via PDGF Receptor β – Integrin α3β1 Interaction", Clin Exp Metastasis, Vol. 16, No. 6, pp. 529-539 (1998). Langerak et al., "Expression of the Wilms' Tumor Gene WTI in Human Malignant Mesothelioma DB Cell Lines and Relationship to Platelet-Derived Growth Factor A and Insulin-Like Growth Factor 2 Expression", Genes Chromosomes Cancer, Vol. 12, No. 2, pp. 87-96 (1995). Langerak, van der Linden-van Beurden and Versnel, "Regulation of Differential Expression of DC Platelet-Derived Growth Factor α- and β-Receptor mRNA in Normal and Malignant Human Mesothelial Cell Lines", Biochim Biophys Acta, Vol. 1305, Nos. 1-2, pp. 63-70 (1996). Langerak et al., "Expression of Platelet-Derived Growth Factor (PDGF) and PDGF Receptors in Human Malignant Mesothelioma in Vitro and in Vivo*, J Pathol, Vol. 178, No. 2, pp. 151-160 DD *Lin et al., "The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor DE PTK787/ZK222584 Inhibits Growth and Migration of Multiple Myeloma Cells in the Bone Marrow Microenvironment", Cancer Res, Vol. 62, No. 17, pp. 5019-5026 (2002). *Maung, "Novel Drugs in Development for Malignant Mesothelioma", Clin Lung Cancer, Vol. 4, DF No. 3, pp. 146-148 (2002). Metheny-Barlow et al., "Paradoxical Effects of Platelet-Derived Growth Factor-A Overexpression in Malignant Mesothelioma. Antiproliferative Effects In Vitro and Tumorigenic Stimulation In Vivo", DG Am J Respir Cell Mol Biol, Vol. 24, No. 6, pp. 694-702 (2001). Pogrebniak, Lubensky and Pass, "Differential Expression of Platelet Derived Growth Factor-β in DH Malignant Mesothelioma: A Clue to Future Therapies?", Surg Oncol, Vol. 2, No. 4, pp. 235-240 (1993).Ruffié, "New Therapeutic Options for Mesothelioma", Rev Pneumol Clin, Vol. 58, No. 5, Pt. 2, pp.3S15-3S18 (2002) - English Translation. DI Syrokou, Tzanakakis, Hjerpe and Karamanos, "Proteoglycans in Human Malignant Mesothelioma. Stimulation of their Synthesis Induced by Epidermal, Insulin and Platelet-Derived Growth Factors DJ Involves Receptors with Tyrosine Kinase Activity", Biochimie, Vol. 81, No. 7, pp. 733-744 (1999). Van der Meeren et al., "Tumorigenic Conversion of Human Mesothelial Cells as a Consequence of Platelet-Derived Growth Factor-A Chain Overexpression", Am J Respir Cell Mol Biol, Vol. 8, No. 2, pp. 214-221 (1993). Versnel et al., "Human Malignant Mesothelioma Cell Lines Express PDGF β-Receptors Whereas DL Cultured Normal Mesothelial Cells Express Predominantly PDGF α-Receptors", Oncogene, Vol. 6, No. 11, pp. 2005-2011 (1991). Zanella, Posada, Tritton and Mossman, "Asbestos Causes Stimulation of the Extracellular Signal-Regulated Kinase 1 Mitogen-Activated Protein Kinase Cascade after Phosphorylation of the DM

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

71e1

Epidermal Growth Factor Receptor", Cancer Res, Vol. 56, No. 23, pp. 5334-5338 (1996).

DATE CONSIDERED